Prosetta

Prosetta is a biotechnology company focused on discovering and developing small molecule therapeutics that target the host-assisted assembly (HAA) of multi-protein complexes. The company's proprietary platform identifies small molecules that modulate the interaction between host cell chaperonins and viral or disease-associated proteins, effectively blocking the assembly of infectious viruses or toxic protein aggregates. Prosetta's pipeline includes programs for a wide range of viral pathogens, including influenza and HIV, as well as neurodegenerative disorders like Alzheimer's and ALS. By targeting host-mediated assembly rather than the viral proteins themselves, the company aims to develop treatments with a high barrier to resistance. The technology is based on decades of research into the fundamental mechanisms of protein biogenesis and trafficking.